--- a
+++ b/clusters/3009knumclusters/clust_122.txt
@@ -0,0 +1,443 @@
+Adequate bone marrow, cardiac, kidney and liver function
+Adequate liver function, including:
+Patients must have adequate renal function with serum creatinine level =< IULN within 21 days prior to registration
+Adequate liver function must be demonstrated, defined as:
+Subjects must have adequate renal function defined as a serum creatinine based on age/gender
+Adequate bone marrow, kidney, and liver function
+Adequate liver function must be demonstrated, defined as:
+Liver function test must be obtained within 14 days prior to registration
+Adequate hematological and biological function, confirmed by the following laboratory values within 96 hours prior to enrollment: Bone Marrow Function
+Adequate bone marrow, renal, and liver function
+Adequate bone marrow, kidney and liver function
+Adequate bone marrow, kidney and liver function
+Acceptable liver function:
+Adequate bone marrow, liver and kidney function
+Adequate renal function as evidenced by a serum/plasma creatinine < 1.5 x ULN
+Acceptable liver function:
+Adequate bone-marrow, renal and liver function.
+Adequate renal function
+Adequate blood coagulation function
+Adequate liver function
+Participants have adequate bone marrow, kidney and liver function.
+Adequate performance status and hematological, liver, and kidney function
+Adequate renal function
+Adequate coagulation function
+Acceptable hematological function:
+Acceptable liver function:
+Adequate bone marrow, kidney and liver function
+Adequate renal function:
+Adequate cardiovascular, hematological, liver and renal function
+Good kidney and liver function
+Adequate liver function:
+Adequate Bone Marrow, Renal, and Liver Function.
+Acceptable liver and renal function
+Must have adequate bone marrow, liver, and renal function as described in protocol
+Adequate renal function
+Adequate liver function
+Adequate bone marrow, cardiac, kidney and liver function
+Adequate renal function
+Acceptable liver function, as specified below:
+Adequate liver function defined by:
+Adequate liver and renal function
+Inadequate liver function as evidenced by any of the following:
+Adequate Bone Marrow, Liver, Renal, Pancreatic Function
+Adequate Renal & Liver Function.
+Adequate renal function within 28 days prior to study registration defined by either of the following criteria:
+Combination Arm: adequate heart function
+Adequate pulmonary and cardiac function
+Adequate renal function.
+Severe impairment of your kidney or liver function
+Hematological function:
+Acceptable liver function at Screening,
+Have acceptable liver function defined as:
+Patients must have adequate bone marrow, kidney, and liver function, (within 14 days prior to registration), defined as:
+Acceptable liver function:
+Acceptable liver function, serum creatinine and hematological status
+Adequate organ function defined as absolute neutrophil count ?1,500×10^6/L, absolute lymphocyte count ?500/mm^3, and platelet count ?100,000×10^6/mm^3. Adequate liver function defined as aspartate aminotransferase and alanine aminotransferase ?2.5× the upper limit of institutional normal, bilirubin ?1.5 mg/dL or 25 µmol/L. Adequate renal function defined as blood urea nitrogen and serum creatinine of ?1.5 mg/dL or 130 µmol/L.
+Subjects must have adequate liver function as defined by:
+Subjects must have adequate renal function
+Adequate bone marrow, liver, renal, and cardiac function at study entry, assessed as follows:
+Adequate cardiac, hematological, liver and renal function
+Adequate bone marrow, renal and liver function
+Adequate liver function as demonstrated by:
+Adequate bone marrow reserve, liver and renal function
+Inadequate renal function as defined by serum creatinine > 3x normal for age
+Acceptable liver function:
+Adequate hematological function, defined as:
+Adequate liver function, defined as:
+Adequate renal function, defined as:
+Adequate coagulation function
+Adequate renal function
+Adequate bone marrows, liver and renal function as assessed by the following laboratory requirements. Hemoglobin ?8.0 g/dL (may not be transfused or treated with erythropoietin in preceding week to maintain or exceed this level)
+Must have adequate coagulation, hematology, kidney, and liver function, per protocol.
+Liver function:
+Adequate renal function.
+Adequate renal function
+Adequate liver function
+Adequate hematological function
+High screening liver function tests
+Adequate renal function:
+Adequate bone marrow, liver, and renal function.
+Adequate renal function including creatinine < 2 unless related to the disease
+Adequate bone marrow, liver, and renal function
+Good kidney and liver function
+Adequate bone marrow, renal, and liver function
+Participant must have adequate liver function as demonstrated by:
+Adequate bone marrow, liver and renal function
+Adequate bone marrow, renal and liver function.
+Subject has adequate liver function defined as:
+Subject has adequate pulmonary function defined as:
+Normal liver, kidney and bone marrow function
+Participants must have adequate renal function, defined as:
+Participants must have adequate liver function, defined as:
+Adequate organ function, hematologic status, coagulation status, kidney function, and liver function as follows:
+Adequate liver function:
+Adequate bone marrow reserve, cardiac, liver, renal and metabolic function:
+Acceptable liver function within 7 days of day 1 of therapy defined as:
+Adequate marrow, liver, and renal function:
+Participant must have adequate liver function as demonstrated by:
+Patients must have adequate bone marrow, liver, coagulation and renal function within 7 days prior to study registration, as defined below:
+Inadequate liver function at screening as demonstrated by the following:
+Adequate renal function
+Renal Function as follows:
+Adequate renal function defined as follows:
+Inadequate liver, renal function as defined below for both cohorts:
+Adequate renal function, as indicated by creatinine =< 1.5 x ULN
+Adequate liver function:
+Adequate renal function:
+Adequate renal function with creatinine (Cr) =< 2.5 mg/dL
+Hematological function:
+Renal function:
+Adequate renal function assessed by: serum creatinine ? 1.5 × ULN
+Adequate renal function: creatinine ?1.5 x ULN
+Impaired renal function
+Reproductive function:
+Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis)
+Adequate bone marrow function, renal and liver functions
+Renal Function:
+Have adequate renal function as defined by the following criterion:
+Adequate marrow function
+Adequate bone marrow, liver and kidney function
+Renal
+Adequate organ function as defined below: • Liver function: a. Total bilirubin < 2.0 mg/dL (34 µmol/L) b. AST and/or ALT <3 x ULN
+Adequate liver function as evidenced by:
+Adequate renal function:
+Adequate Renal Function:
+Adequate Liver Function:
+Evidence of inadequate renal function (creatinine > 2 g/dL)
+Renal function: preservation of renal function, serum creatinine did NOT increase by more than 2 fold above the normal reference range
+Renal function criteria: preservation of renal function, serum creatinine did NOT increase by more than 2 fold above the normal reference range
+Subjects must have adequate liver function as defined by:
+Subjects must have adequate renal function defined as: Serum creatinine based on age/gender.
+Patients are required to have adequate renal function as indicated by a serum creatinine =< 2.5 mg/dL; this value must be obtained within four weeks before protocol entry
+Adequate bone marrow, liver, renal and coagulation function
+Impaired heart function
+Acceptable liver function
+Acceptable renal function
+Patient must have adequate renal function as defined by serum creatinine < -2.5 mg/dl obtained within 28 days prior to registration
+Liver function test must be obtained within 14 days prior to registration
+Renal Function: Adequate renal function in the opinion of the Investigator with no clinically significant renal impairment or uncontrolled renal disease.
+Immunological Function: Adequate immune system function in the opinion of the Investigator with no known immunodeficiency disease.
+Adequate bone marrow, renal and liver function.
+Adequate renal function, defined as:
+Adequate liver function, defined as:
+Adequate liver function at Cycle 1 Day 1 pre-dosing defined as:
+Acceptable renal function
+Acceptable liver function
+Adequate hematological, liver and kidney function.
+Adequate hematological, liver, and kidney function
+Adequate liver and renal function
+Acceptable liver function
+Adequate renal, liver and bone marrow function:
+Have adequate values, bone marrow, renal and liver functions at screening as defined below:
+Adequate liver and renal function and hematology laboratory values
+Adequate liver function
+Adequate renal function
+Adequate bone marrow, renal and liver function.
+Adequate bone marrow, liver, and renal function, as documented by the following laboratory assessments conducted within 28 days prior to dosing:
+Adequate bone marrow, liver and renal function.
+The patient has adequate pulmonary function
+Adequate renal functions
+Patients must have adequate renal function defined as age-adjusted serum creatinine =< 1.5 x normal for age
+Have adequate renal function
+Patient has adequate bone marrow, coagulation, liver and renal function
+Acceptable renal function
+Acceptable liver function
+Adequate performance status and hematological, liver and kidney functions
+Adequate liver and renal function
+Adequate bone marrow function (absolute neutrophil count > 1,500/mm3 and platelet count of > 100,000/mm3), adequate liver function [ALT and AST <3 x upper limit normal (ULN), alkaline phosphatase <2 x ULN, and total bilirubin <1.5 mg/dL], & adequate renal function (BUN and creatinine <1.5 x ULN)
+Adequate bone marrow, liver, kidney function
+Liver function < 3 x normal
+Renal function: CrCl < 15 ml/min.
+Adequate renal function: serum creatinine =< 1.5 x ULN
+Inadequate lung function
+Inadequate renal function
+Subject has adequate renal function, which is defined as:
+Subjects must have adequate hematopoietic function as evidenced by:
+Subjects must have adequate liver function, including all of the following:
+Adequate bone marrow, kidney and liver function
+Patients must have adequate heart, kidney, liver and bone marrow function.
+Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.
+Adequate hematological, renal, and liver function
+Subject must have adequate kidney and liver function as described in the protocol
+Renal function defined as:
+Liver function defined as:
+Have adequate coagulation function.
+Have adequate renal function as defined by creatinine clearance >30 milliliters/minute.
+Adequate hematological, liver, and renal function
+Adequate renal function, defined as serum creatinine ?1.5x ULN or GFR >50 mL/min
+Acceptable liver and renal function:
+Adequate liver function:
+Adequate blood clotting function
+Bone marrow impairment, renal impairment, liver function abnormality and impaired cardiac function as defined in the protocol
+Adequate liver function
+Abnormal liver function test results
+Adequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)
+Adequate hematological, liver and kidney function.
+Adequate cardiovascular function
+Adequate renal, liver, and bone marrow function according to the following criteria:
+Inclusion Criteria:\n\n        Patients with histologically or cytologically confirmed advanced solid malignancy or\n        Lymphoma\n\n        Relapsed or refractory disease after at least 1 prior systemic treatment for the primary\n        malignancy and not a candidate for other curative treatment.\n\n        Adequate hematologic status\n\n        Adequate coagulation function\n\n        Adequate hepatic function\n\n        Adequate renal function\n\n        Exclusion Criteria:\n\n        Known primary tumors of central nervous system disease\n\n        Known active brain metastases\n\n        Known cardiopulmonary disease
+Adequate liver, bone marrow and renal function
+Adequate liver function:
+Participants with Hepatitis B or C are eligible on the condition that they have adequate liver function as defined by Inclusion Criterion 9.
+Adequate bone marrow, renal, liver and pancreatic function
+Adequate liver and renal function
+Have adequate organ function including hematology, renal, and liver.
+Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements:
+Abnormal hematological, renal, or liver function
+Adequate liver function
+Adequate renal function
+Renal function: • Creatinine less than or equal to 1.5 x ULN
+Inadequate renal or liver function
+Acceptable renal function
+Acceptable liver function
+Adequate bone marrow, kidney and liver function
+Adequate liver function, defined as:
+Adequate cardiac function as assessed clinically
+Adequate cardiac function as measured by echocardiogram
+Inadequate hematological, liver, renal, cardiac function
+Adequate coagulation function
+Adequate renal function
+Eligible study subjects must exhibit acceptable liver, renal, and coagulation function as assessed by laboratory tests.
+Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac function parameters outside protocol-defined range
+Inadequate hematologic function, renal function, and liver function
+Adequate bone marrow, liver and renal function
+Adequate renal function (defined as serum creatinine =< 1.5 X ULN)
+Adequate bone marrow function, renal and liver functions
+Adequate hematological and biological function
+Adequate liver, kidney, and bone marrow function
+Adequate bone marrow, liver and renal function
+Adequate bone marrow, liver, and renal functions.
+Adequate renal function within 28 days prior to registration for protocol therapy defined by either of the following criteria:
+Inadequate liver, renal or bone marrow function within 2 weeks of first dose
+Patient has adequate renal function defined as: Serum creatinine ?1.5 the institutional ULN
+Inadequate renal function
+Subject must have adequate liver function as demonstrated by:
+Adequate liver function
+Inadequate renal function
+Renal
+Inadequate bone marrow, renal, or liver function
+Adequate hematological function defined as:
+Adequate liver function defined as:
+Acceptable liver function defined as:
+Adequate bone marrow, kidney and liver function.
+Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function
+Adequate liver function, defined as both of the following:
+Adequate bone marrow, renal, and liver function.
+Adequate renal function
+Adequate liver function
+Adequate cardiac function
+Adequate neurologic function
+Adequate pancreatic function
+Adequate liver function, defined as:
+Adequate bone marrow, liver and renal function renal function
+Adequate cardiac function
+Adequate bone marrow, liver and renal function as assessed by the following laboratory tests conducted within 7 days before randomization.
+Abnormal heart function
+Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment
+Adequate renal function, defined as serum creatinine ?1.5x ULN
+Adequate renal function
+Adequate organ function (bone marrow, kidney and liver)
+Adequate kidney function
+Adequate liver function
+Normal pancreatic function
+Patients must have adequate renal function (creatinine < 1.5 mg/dL) before starting therapy and the test must be performed within 14 days prior to registration
+Renal
+Inadequate liver function at screening and Day 1 (before drug administration) as demonstrated by:
+Adequate haematological, renal (creatinine < 2xULN), cardiac and liver functions
+Abnormal/inadequate blood values, liver and kidney function
+Adequate cardiac and renal function
+abnormal/inadequate blood values, liver, and kidney function
+Adequate liver function (bilirubin less than or equal to 3.0 mg/dl, unless considered due to tumor), and renal function (creatinine less than or equal to 3.0 mg/dl, unless considered due to tumor)
+Adequate cardiac function as assessed clinically.
+Adequate Bone Marrow, Renal and liver Functions.
+Adequate liver, kidney, and bone marrow function
+Participants must have adequate liver, kidney, and bone morrow function
+Adequate bone marrow, renal and liver function.
+Adequate hematological, liver and kidney function.
+Adequate renal function.
+Adequate glucose control, bone marrow, kidney, liver, and heart function.
+Inadequate heart function
+Inadequate lung function
+Adequate hematological function, defined as:
+Adequate liver function, defined as:
+Adequate bone marrow, liver and renal function
+Adequate hematological function, defined as:
+Adequate liver function, defined as:
+Adequate hematological, liver, and renal function
+Adequate bone marrow, liver and renal function
+Adequate renal and liver function
+Must have adequate hematological function
+Must have adequate renal function
+Patients must be suitable candidates for treatment with standard regimens; this includes having adequate hematologic parameters, liver function and renal function based on labs that are deemed acceptable for treatment by the investigators
+Adequate bone marrow, kidney and liver function
+Severe impairment of your kidney or liver function
+Adequate white blood cell counts (with low blast counts), liver function, and renal function
+Acceptable hematological status, liver and renal function as defined in the protocol
+Adequate bone marrow function [absolute neutrophil count (ANC) > 1,500/mm3 & platelet count of > 100,000/mm3], adequate liver function [alanine aminotransferase (ALT) & aspartate aminotransferase (AST) <3 x upper limit normal (ULN), alkaline phosphatase <2 x ULN, & total bilirubin <1.5 mg/dL], & adequate renal function (BUN & creatinine <1.5 x ULN)
+Adequate bone marrow, renal, liver, cardiac and pulmonary function.
+Inadequate renal function (Blood creatinine > 1.5 times the institutional ULN)
+Adequate renal function
+Have adequate bone marrow function, liver function, and renal function, as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:
+Adequate bone marrow, kidney, liver, and heart function.
+Acceptable liver function
+Acceptable renal function
+Adequate renal function
+Acceptable liver function:
+Adequate bone marrow, liver and renal function
+Adequate renal function, defined by serum creatinine ? 1.5 x ULN.
+Adequate hematological, renal and liver function
+Patients must have adequate liver function
+Patients must have adequate renal function as defined by a serum creatinine =< 1.5 times ULN within one week prior to treatment
+Adequate bone marrow, liver and renal function
+Adequate coagulation function as defined by the following criteria:
+Adequate blood, liver, and kidney function as defined by laboratory tests.
+Subjects must have adequate liver function
+Subjects must have adequate kidney function
+Adequate bone marrow, liver, and renal function
+Adequate liver function, defined as:
+Patients must have adequate bone marrow function (ANC >/= 1,500/mm3 and platelet count of >/= 100,000/mm3), adequate liver function (SGPT and serum glutamate oxaloacetate transaminase (SGOT) </= 2.5 times normal, bilirubin </= 2 mg/dl), and adequate renal function (BUN and creatinine </=1.5 times institutional normal) prior to starting therapy.
+Adequate bone marrow, liver, and renal functions
+Adequate bone marrow, liver, and renal functions, defined as:
+Inadequate hematopoietic, liver, endocrine or renal function
+Inadequate lung function
+Inadequate heart function
+Adequate bone morrow and kidney function
+Adequate bone marrow, liver, cardiac, and renal function
+Adequate haematological, liver and renal function
+Adequate renal function
+Adequate liver, renal and cardiac function
+Adequate bone marrow, kidney and liver function
+Patient must have adequate renal function documented by a serum creatinine of ? 1.5 times the ULN for the reference lab.
+Adequate hematological, renal and liver function For solid tumors only:
+Impaired bone marrow, liver or renal function (as defined by protocol)
+Reproductive Function
+Adequate renal function
+Adequate liver function
+Adequate cardiac function
+normal immune function
+Acceptable bone marrow, liver and kidney function.
+Adequate renal function
+Adequate liver function within 72 hours of enrollment, defined as:
+Adequate renal function, defined as serum creatinine ? 1.5x ULN
+Adequate hematological and biological function; LVEF ?50%
+Acceptable renal function
+Acceptable liver function
+Adequate cardiac function:
+Inadequate bone marrow, liver, and renal function, as assessed by the following laboratory parameters:
+Impaired heart function
+Adequate bone marrow, renal and liver functioning
+Chemistry, liver function tests, renal function, total CPK and hematology lab results must be ? Grade 1 at the time of screening;
+Adequate bone marrow and renal function
+Adequate bone marrow, renal and liver function
+Adequate bone marrow, kidney, and liver function
+Adequate hematology, liver and renal function laboratory values within 14 days prior to first dose of study treatment.
+Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment:
+Adequate liver function as demonstrated by
+Have adequate complete blood counts and liver function tests
+Have adequate cardiac function
+Has adequate organ function (bone marrow, kidney and liver)
+Inadequate lung function
+Adequate bone marrow, and liver function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment
+For subjects with SEVERELY IMPAIRED renal function:
+Protocol-defined renal , liver and bone marrow function
+Adequate hematological function (as defined in the study protocol)
+Adequate renal function (as defined in the study protocol)
+Adequate liver function (as defined in the study protocol)
+Have adequate cardiac, bone marrow, liver and kidney function
+Abnormal heart function
+Renal:
+Adequate bone marrow, liver, and renal function within the 14 days prior to Day 1 of Cycle 1 of study drug up until pre-dose of Cycle 1
+Renal function, as follows:
+Liver function:
+Renal function:
+Adequate hematological function unless inadequate function is due to underlying disease
+Adequate bone marrow, liver, and renal function
+Adequate hematological and biological function
+Abnormal renal function tests (creatinine > 1.5)
+Inclusion Criteria:\n\n          -  Life expectancy of at least 3 months\n\n          -  Histological or cytological documentation of advanced solid tumors\n\n          -  ECOG Performance Status of ? 1 (ECOG: Eastern Cooperative Oncology Group)\n\n          -  Adequate bone marrow, liver and renal function\n\n          -  Women of childbearing potential and men must agree to use adequate contraception
+Adequate liver and renal functions
+Hematological function, as follows:
+Adequate hematological, renal and liver function
+Adequate hematological function
+Adequate renal function:
+Normal renal function: estimated CrCl ?90 ml/min
+Participants with adequate hematological, liver, and renal function
+Adequate liver function, defined as:
+Adequate bone marrow, renal and liver function as defined in the protocol.
+Renal Function Creatinine >1.5 mg%
+Adequate bone marrow, liver and renal function
+Adequate liver function, as indicated by bilirubin =< 1.5 x ULN
+Adequate Renal function
+Inadequate kidney, liver, blood clotting function
+Adequate renal function.
+Adequate cardiac function.
+Adequate renal function.
+Adequate pulmonary function
+Patients must have acceptable neutrophil and platelet counts as well as adequate kidney and liver function.
+Inadequate liver function as evidenced by any of the following:
+Hepatic and renal function meeting the strata as outlined below; nota bene (NB): patients must fulfill both total bilirubin and serum glutamic-oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) criteria and creatinine function to be included in a group; however, if a patient’s total bilirubin and SGOT/AST and creatinine levels indicate different groups, the patient may be enrolled in the indicated group with the greatest degree of liver dysfunction; all liver and renal function tests must be completed within 24 hours prior to the start of treatment; Note: patients on dialysis will not be eligible\r\n* Group A: hepatic function: normal function (bilirubin =< upper limit of normal [ULN]; AST =< ULN); renal function: normal function (creatinine clearance [CrCl] >= 60 mL/min) \r\n* Group B: hepatic function: normal function (bilirubin =< ULN; AST =< ULN); renal function: moderate dysfunction (CrCl >= 30 and < 60 ml/min)\r\n* Group C: hepatic function: normal function (bilirubin =< ULN; AST =< ULN); renal function: severe dysfunction (CrCl >= 15 and < 30 ml/min)\r\n* Group D: hepatic function: mild dysfunction D1: bilirubin =< ULN; AST > ULN, D2: bilirubin > ULN and =< 1.5 x ULN; any AST; renal function: normal function (creatinine clearance [CrCl] >= 60 mL/min)\r\n* Group E: hepatic function: mooderate dysfunction (bilirubin 1.5 x > ULN and =< 3 x ULN; any AST); renal function: normal function (creatinine clearance [CrCl] >= 60 mL/min)\r\n* Group F: hepatic function: severe dysfunction (bilirubin > 3 x ULN and up to investigator’s discretion; any AST); renal function: normal function (creatinine clearance [CrCl] >= 60 mL/min)
+Patients with solitary kidneys, bilateral renal tumors, compromised renal function (baseline creatinine > 1.4)
+Have adequate liver function defined as:
+Have adequate heart function defined as:
+Adequate hematologic and organ function, including blood counts, liver and kidney function Stage I Arm A (GDC-0077):
+Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation.
+Adequate liver function:
+Impaired heart function
+Normal kidney and liver function (lab results must be within 45 days prior enrollment)
+Adequate renal and liver function as indicated by:
+Adequate bone marrow, liver, and renal function, as assessed by the following requirements conducted within 21 days prior to dosing:
+Adequate bone marrow, liver, and renal functions
+Adequate bone marrow, liver, cardiac, and renal function
+Patients must have normal renal function test and no prior renal disease; the screening cut off for serum creatinine is < 1.5 mg/dL
+Patients with normal renal function according to MD Anderson testing standards and no prior renal disease
+Adequate bone marrow, liver, and renal function
+Adequate bone marrow, liver and kidney function
+Participants with renal insufficiency or failure, as determined by a point of care renal function blood test.
+Liver: Subjects must have adequate liver function
+Renal: Adequate renal function
+Cardiac and pulmonary function that is adequate for ASCT
+Adequate renal function
+Adequate hematological, liver and kidney function.
+Adequate bone marrow reserves and liver and kidney function, as assessed by the following laboratory requirements:
+Compromised renal function
+Patients must have adequate liver function as defined by AST or ALT <10x normal
+Have adequate bone marrow reserves and liver and kidney function, as assessed by the following laboratory requirements:
+Inadequate renal function
+Adequate renal function: serum creatinine ? 1.5x ULN;
+Adequate bone marrow, liver and renal function
+Participants with renal insufficiency or failure, as determined by a point of care renal function blood test
+Adequate performance status and hematological, liver, and kidney function
+Good kidney and liver function
+Adequate renal function within 28 days prior to C1D1
+Adequate hematopoietic function within 7 days prior to C1D1
+Adequate bone marrow, liver, and kidney function within 2 weeks prior to first dose
+Adequate liver function:
+Adequate hematological, liver, and renal functions
+Adequate renal function defined as:
+Adequate liver function defined as:
+Adequate function of kidney:
+Adequate function of liver:
+Adequate liver function:
+Adequate bone marrow, kidney and liver function
+Adequate bone marrow, liver, and renal function